Passage Bio, Inc.
PASG · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $3,721 | $0 | $0 |
| Gross Profit | $0 | -$3,721 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $40,179 | $59,556 | $86,053 | $117,673 |
| G&A Expenses | $24,988 | $41,580 | $49,341 | $60,056 |
| SG&A Expenses | $24,988 | $41,580 | $49,341 | $60,056 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $5,233 | -$4,721 | $3,000 | $8,000 |
| Operating Expenses | $70,400 | $96,415 | $138,394 | $185,729 |
| Operating Income | -$70,400 | -$100,136 | -$138,394 | -$185,729 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $5,633 | -$1,926 | $2,269 | $343 |
| Pre-Tax Income | -$64,767 | -$102,062 | -$136,125 | -$185,386 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$64,767 | -$102,062 | -$136,125 | -$185,386 |
| % Margin | – | – | – | – |
| EPS | -21.44 | -37.29 | -50 | -69.51 |
| % Growth | 42.5% | 25.4% | 28.1% | – |
| EPS Diluted | -21.44 | -37.29 | -50 | -69.51 |
| Weighted Avg Shares Out | 3,020 | 2,737 | 2,721 | 2,667 |
| Weighted Avg Shares Out Dil | 3,020 | 2,737 | 2,721 | 2,667 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,300 | $5,600 | $2,269 | $343 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3,081 | $3,721 | $3,679 | $1,543 |
| EBITDA | -$62,086 | -$98,341 | -$131,715 | -$176,186 |
| % Margin | – | – | – | – |